Login to Your Account



Takeda bags ex-U.S. rights to Tigenix cell therapy for Crohn's disease in $432M deal

By Cormac Sheridan
Staff Writer

Tuesday, July 5, 2016

DUBLIN – Shares in Tigenix NV gained 23 percent Tuesday on news of a sizeable ex-U.S. deal with Takeda Pharmaceutical Co. Ltd. for its allogeneic cell therapy for Crohn's disease, Cx601.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription